Inhalable curcumin: offering the potential for translation to imaging and treatment of Alzheimer's disease.

McClure R, Yanagisawa D, Stec D, Abdollahian D, Koktysh D, Xhillari D, Jaeger R, Stanwood G, Chekmenev E, Tooyama I, Gore JC, Pham W
J Alzheimers Dis. 2015 44 (1): 283-95

PMID: 25227316 · PMCID: PMC4297252 · DOI:10.3233/JAD-140798

Curcumin is a promising compound that can be used as a theranostic agent to aid research in Alzheimer's disease. Beyond its ability to bind to amyloid plaques, the compound can also cross the blood-brain barrier. Presently, curcumin can be applied only to animal models, as the formulation needed for iv injection renders it unfit for human use. Here, we describe a novel technique to aerosolize a curcumin derivative, FMeC1, and facilitate its safe delivery to the brain. Aside from the translational applicability of this approach, a study in the 5XFAD mouse model suggested that inhalation exposure to an aerosolized FMeC1 modestly improved the distribution of the compound in the brain. Additionally, immunohistochemistry data confirms that following aerosol delivery, FMeC1 binds amyloid plaques expressed in the hippocampal areas and cortex.

MeSH Terms (17)

Administration, Inhalation Alzheimer Disease Amyloid beta-Protein Precursor Animals Anti-Inflammatory Agents, Non-Steroidal Brain Curcumin Diagnostic Imaging Disease Models, Animal Humans Mice Mice, Inbred C57BL Mice, Transgenic Mutation Plaque, Amyloid Presenilin-1 Tissue Distribution

Connections (4)

This publication is referenced by other Labnodes entities: